setmelanotide · Imcivree
Peptide
Also known as RM-493, BIM-22493
Evidence outlook
Approved: Obesity (label: acquired hypothalamic obesity, Bardet-Biedl syndrome, and POMC, PCSK1 or LEPR deficiency obesity), Bardet-Biedl Syndrome, Hypothalamic Obesity
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Prader-Willi Syndrome · Phase 2 · investigational in the US
Also approved (5)
- Acquired hypothalamic obesity (first therapy approved in Japan for it)
- Weight management in patients 6 years and older with obesity due to Bardet-Biedl syndrome or genetically confirmed POMC, PCSK1 or LEPR deficiency
- Obesity and control of hunger with genetically confirmed POMC/PCSK1 or LEPR deficiency, and Bardet-Biedl syndrome; later extended to acquired hypothalamic obesity
- Obesity and control of hunger with genetically confirmed Bardet-Biedl syndrome, adults and children from 2 years
- Obesity and control of hunger in acquired hypothalamic obesity, from 4 years (extension)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02896192 NCT02896192 · Pro-opiomelanocortin (POMC) Deficiency Obesity The study was an open-label, single-group trial of 15 participants; although it included a short double-blind placebo-withdrawal period, the primary one-year weight-loss endpoint was assessed without a parallel placebo or active-control arm. The primary endpoint was statistically positive against a predefined 5% benchmark, but the uncontrolled design limits the strength of evidence. Registry: NCT02896192 | 3 | Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52) 2020-05-25 | Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 80% (95% CI 49.31 to 96.32) | Weak signal | link ↗ |
View 4 more trials
NCT03287960 NCT03287960 · Leptin Receptor Deficiency Obesity The primary one-year outcome was assessed in an open-label, single-group study of 15 participants, without a concurrent control arm or randomized comparison. Although 45.5% of the pivotal cohort reached at least 10% weight loss and the registry reports a significant comparison with a 5% benchmark, the study’s primary efficacy assessment was not a controlled between-group trial. Registry: NCT03287960 | 3 | Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52) 2020-09-25 | Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88) | Weak signal | link ↗ |
NCT05774756 NCT05774756 · Obesity This was a randomized, triple-blind, placebo-controlled trial whose primary endpoint, percent change in BMI, was clearly met (difference of about 20 percentage points, p<0.0001). The trial enrolled the 120 pivotal participants its reported power calculation required. Registry: NCT05774756 | 3 | Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)) 2025-03-18 | Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) | Reliable signal | link ↗ |
NCT03746522 NCT03746522 · Obesity The study had randomized, quadruple-blind, placebo-controlled treatment initially, but its primary 52-week weight-loss endpoint was assessed after the placebo group switched to open-label setmelanotide and was reported for a single pivotal cohort rather than as a direct randomized comparison. The endpoint was clinically meaningful and the reported result favored treatment, but the provided record does not report a primary-endpoint power calculation, so the evidence is graded moderate rather than strong. Registry: NCT03746522 | 3 | Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort (52 weeks) 2020-11-16 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT04966741 NCT04966741 · Obesity The study was open-label and had no comparator arm, so its results are uncontrolled despite the registry describing randomized allocation; it included only 12 participants (7 PPL and 5 with Bardet-Biedl syndrome). The primary BMI outcomes were reported as favorable within each setmelanotide group, but without a control group there was no formal treatment comparison to assess. Registry: NCT04966741 | 3 | Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 (Baseline up to Week 52); Mean Percent Change From Baseline in BMI (Baseline, Week 52) 2023-09-18 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Competitive landscape
Other MC4R drugs
bivamelagon, bremelanotide, RM-718. Compare all 4 MC4R drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Hypothalamic Obesity: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Setmelanotide (Imcivree): this drug | Approved | Peptide | MC4R | Reliable signal | NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) | |
| Bivamelagon | Phase 2 | Small molecule | MC4R | Partial signal | NCT06046443: Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2% |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Imcivree (setmelanotide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2030 (1)
December 2030 (1)
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent